ライフサイエンスコーパス: interleukin-15

1 otential and dependence on the growth factor interleukin 15.

2 ed by induction of a second cytokine such as interleukin 15.

3 values areas under the curve >0.70 including interleukin 15.

4 IFN-gamma production, which was enhanced by interleukin 15.

5 anced expansion with endogenous or exogenous interleukin 15.

6 alloantigens and dendritic cells and require interleukin-15.

7 ignalling downstream of CAR activation or by interleukin-15.

8 factor, platelet-derived growth factor, and interleukin-15.

9 amma directly ex vivo; and were dependent on interleukin-15.

10 In the epithelium, interleukin-15 activates intraepithelial lymphocytes tha

11 N-formyl-methionyl-leucyl-phenylalanine, and interleukin 15, adhesion molecules P-selectin glycoprote

12 CD11c(+)NK1.1(+) cells depended primarily on interleukin 15 and common cytokine receptor gamma chain

13 y production of tumor necrosis factor-alpha, interleukin-15 and interleukin-1alpha, and transforming

14 ing CT-defined small airway abnormality, and interleukin-15 and interleukin-8 concentrations.

15 This division requires interleukin-15 and is markedly increased by inhibition o

16 and obese mGHRKO mice demonstrated a higher interleukin-15 and lower myostatin expression relative t

17 mer nanoparticles encapsulating the cytokine interleukin-15 and platelets conjugated with the checkpo

18 to SVZ neural stem cells (NSCs) that produce interleukin-15 and sustain functionally competent NK cel

19 d siblings in the presence of interleukin 2, interleukin 15, and rapamycin.

20 nterleukin-18, interferon-gamma and possibly interleukin-15, and a cross-talk between B lymphocytes a

21 ses, responses of interferons, production of interleukin-15, and expression of tumor necrosis factor-

22 expressing genes that encode anti-CD19 CAR, interleukin-15, and inducible caspase 9 as a safety swit

23 evels of monocyte chemoattractant protein-1, interleukin-15, and interleukin-12/23 were also elevated

24 1, soluble FAS, tumor necrosis factor-alpha, interleukin-15, and interleukin-1beta) and death with fu

25 ector cells (T(CM/E)) was dependent on human interleukin-15, and superior in magnitude and duration t

26 y of adoptively transferred T lymphocytes by interleukin-15, and the safe use of dendritic cell-deriv

27 tions were also performed with mRNA encoding interleukin-15 as a potential immunotherapy agent and ag

28 sing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15) in 37 patients with CD19(+)

29 dominant peptide induced rapid expression of interleukin-15, CD83, cyclo-oxygenase (COX)-2, and CD25

30 nce of small airway abnormality on CT, lower interleukin-15 concentrations, and higher interleukin-8

31 oid system of transgenic mice overexpressing interleukin-15 could be visualized.

32 e-based strategies such as interleukin-2 and interleukin-15 derivatives; and (iii) antibody-based the

33 xicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation.

34 nterleukin-6, interleukin-8, interleukin-10, interleukin-15, eotaxin-3, interferon gamma-induced prot

35 tion receptor (NKAR) stimulation and chronic interleukin-15 exposure impart distinct modes of dysregu

36 This interaction led to the inhibition of interleukin-15 expression in CAFs, suppressing the infil

37 MIP-2 and KC at the site of infection, while interleukin-15 expression remained relatively unchanged

38 onally, these cells express a membrane-bound interleukin-15 fusion molecule to enhance function and p

39 or cytokine genes such as interleukin-12 and interleukin-15 genes enhances the efficacy of the vector

40 C57BL/6 mice genetically deficient in interleukin 15 (IL-15(-/-) mice) were generated by gene

41 lls when CD28 down-regulation was induced by interleukin 15 (IL-15) and IL-12 stimulation.

42 We show that co-expression of interleukin 15 (IL-15) and IL-15 receptor alpha (IL-15Ra

43 Interleukin 15 (IL-15) and IL-2 have distinct immunologi

44 Interleukin 15 (IL-15) and the IL-15 receptor alpha (IL-

45 cing identified interferon gamma (IFN-y) and interleukin 15 (IL-15) as cytokines with activity both h

46 Two isoforms of human interleukin 15 (IL-15) exist.

47 Lately, interleukin 15 (IL-15) has been implicated both in osteo

48 Increased expression of interleukin 15 (IL-15) in leukemic blasts is associated

49 s developed and used to evaluate the role of interleukin 15 (IL-15) in the modulation of the therapeu

50 Interleukin 15 (IL-15) is a critical factor for the prol

51 Interleukin 15 (IL-15) is a novel cytokine with interleu

52 Interleukin 15 (IL-15) is an essential cytokine for the

53 Interleukin 15 (IL-15) is implicated in the pathophysiol

54 Interleukin 15 (IL-15) is one of the most important cyto

55 f coeliac disease with high mortality rates; interleukin 15 (IL-15) is strongly implicated in its pat

56 Interleukin 15 (IL-15) mRNA is expressed in a wide varie

57 Given the central role that interleukin 15 (IL-15) plays in human immunodeficiency v

58 We show here that interleukin 15 (IL-15) potently inhibits spontaneous and

59 ia compared with normoxia and in response to interleukin 15 (IL-15) priming using a 2 x 2 factorial d

60 nfiltration of proliferating NK cells due to interleukin 15 (IL-15) released and presented by the can

61 g (CIS) protein, a key negative regulator of interleukin 15 (IL-15) signaling, with fourth-generation

62 e recalled and boosted by treatment with the interleukin 15 (IL-15) superagonist N-803 after ART disc

63 ferent CD4(+) T cell subsets stimulated with interleukin 15 (IL-15), a cytokine that increases both s

64 Interleukin 15 (IL-15), a cytokine that shares many biol

65 this process by limiting the availability of interleukin 15 (IL-15), and administration of IL-15/IL-1

66 The production of interleukin 15 (IL-15), IL-18, gamma interferon (IFN-gam

67 ls from bone marrow precursor cells requires interleukin 15 (IL-15); however, very little is known ab

68 oth the tdTomato red fluorescent protein and interleukin-15 (IL-15) (vMyx-IL-15-tdTr) was constructed

69 Interleukin-15 (IL-15) and direct contact between the tu

70 Importantly, UV-HSV-1 synergizes with interleukin-15 (IL-15) and IL-2 in inducing activation a

71 nstrated that NK cells cultured ex vivo with interleukin-15 (IL-15) and nicotinamide (NAM) exhibited

72 cells generated in vitro in the presence of interleukin-15 (IL-15) and/or IL-2 from umbilical cord b

73 Interleukin-2 (IL-2) and interleukin-15 (IL-15) are T-cell tropic factors that sh

74 ed to be mediated primarily by production of interleukin-15 (IL-15) by the mature DCs.

75 Several studies have provided evidence that interleukin-15 (IL-15) can enhance protective immune res

76 We now report that interleukin-15 (IL-15) can induce TNF-alpha production i

77 Dosing with interleukin-15 (IL-15) enhanced NK cell cytotoxicity in

78 ntiation of intratumoural ILTCKs depended on interleukin-15 (IL-15) expression in cancer cells, and i

79 nflammatory activity in the tissues and with interleukin-15 (IL-15) expression.

80 hematopoietic precursor cells (HPCs) require interleukin-15 (IL-15) for differentiation into human NK

81 activation and were associated with enhanced interleukin-15 (IL-15) gene expression, suggesting a pat

82 ion studies have consistently implicated the interleukin-15 (IL-15) gene in acute lymphoblastic leuke

83 Interleukin-15 (IL-15) has significant potential in canc

84 ription (STAT) factor activation mediated by interleukin-15 (IL-15) in cells isolated from aviremic p

85 r frequencies in murine thymus and depend on interleukin-15 (IL-15) in periphery.

86 dentified a previously unrecognized role for interleukin-15 (IL-15) in red blood cell homeostasis and

87 studies have suggested an important role for interleukin-15 (IL-15) in resistance to and memory for T

88 ouse models demonstrate the critical role of interleukin-15 (IL-15) in T-LGLL pathogenesis.

89 model that reproduces the overexpression of interleukin-15 (IL-15) in the gut epithelium and lamina

90 Interleukin-15 (IL-15) in vitro treatment of peripheral

91 Interleukin-15 (IL-15) is a 14- to 15-kDa member of the

92 Interleukin-15 (IL-15) is a cytokine with potential ther

93 Interleukin-15 (IL-15) is a gamma-common cytokine that p

94 Interleukin-15 (IL-15) is a newly described cytokine tha

95 Interleukin-15 (IL-15) is a pleiotropic proinflammatory

96 Interleukin-15 (IL-15) is a pro-inflammatory cytokine el

97 Interleukin-15 (IL-15) is a pro-inflammatory cytokine ex

98 Interleukin-15 (IL-15) is a recently identified growth a

99 Because interleukin-15 (IL-15) is an essential cytokine for NK c

100 Interleukin-15 (IL-15) is an important lymphokine regula

101 Because interleukin-15 (IL-15) is crucial for iNKT development a

102 Interleukin-15 (IL-15) is crucial for the development of

103 Interleukin-15 (IL-15) is essential for natural killer (

104 Interleukin-15 (IL-15) is essential for the development

105 Interleukin-15 (IL-15) is often considered a central reg

106 mphopenia in all patients and an increase in interleukin-15 (IL-15) levels in 6 out 8 patients.

107 analyses have shown increased expression of interleukin-15 (IL-15) messenger RNA in the esophagus of

108 sis factor (TNF) and trans-presented (trans) interleukin-15 (IL-15) on DCs, leading to enhanced NK ce

109 progenitors with AFT024 and the addition of interleukin-15 (IL-15) or IL-2 but not IL-7.

110 emonstrate that activation of NK cells using interleukin-15 (IL-15) plus 4-1BBL upregulates activatin

111 Interleukin-15 (IL-15) produced by and trans-presented o

112 Interleukin-15 (IL-15) promoted ILC1 granzyme A expressi

113 ng clonal expansion and contraction, whereas interleukin-15 (IL-15) promoted their survival only duri

114 upstream of an NF-kappaB binding site in the interleukin-15 (IL-15) promoter.

115 Interleukin-15 (IL-15) promotes expansion and activation

116 The cytokine interleukin-15 (IL-15) promotes proliferation and effect

117 Interleukin-15 (IL-15) promotes the survival of T lympho

118 , and he was investigated for defects in the interleukin-15 (IL-15) receptor complex because function

119 enes such as NOTCH1 and RBPJ, as well as the interleukin-15 (IL-15) receptor complex, the latter enha

120 he gene CISH) is a key negative regulator of interleukin-15 (IL-15) signaling in natural killer (NK)

121 Interleukin-15 (IL-15) signaling induced miR-142 express

122 The cytokine interleukin-15 (IL-15) signals through the formation of

123 Interleukin-15 (IL-15) stimulates the diffrentiation and

124 moter element is significantly enhanced upon interleukin-15 (IL-15) stimulation in peripheral blood N

125 oing CD8alpha depletion and treated with the interleukin-15 (IL-15) superagonist N-803 (J.

126 ted by activating them via treatment with an interleukin-15 (IL-15) superagonist, IL-15 bound to solu

127 Low doses of interleukin-15 (IL-15) that mimic exercise responses in

128 ax vaccine, we generated a recombinant Wyeth interleukin-15 (IL-15) with integrated IL-15, a cytokine

129 Interleukin-15 (IL-15), a 114-amino acid cytokine relate

130 We found that interleukin-15 (IL-15), a cytokine critical for CD8(+) m

131 y aspect of NK cell immunity is regulated by interleukin-15 (IL-15), a cytokine in the common gamma-c

132 Interleukin-15 (IL-15), a product of monocytes and other

133 ations in immune regulatory genes, including interleukin-15 (IL-15), IL-6ST, STAT5B, HIVEP1, and IL-9

134 operties of alpha interferon (IFN-alpha) and interleukin-15 (IL-15), this study explored the therapeu

135 pression of the CXCR3 ligand MIG (CXCL9) and interleukin-15 (IL-15), type I interferon (IFN)-inducibl

136 1 with a mesothelin (MSLN)-targeting CAR and interleukin-15 (IL-15), we achieved robust differentiati

137 the CD19 antigen in the presence of CD80 and interleukin-15 (IL-15).

138 ress and trans-present the survival cytokine interleukin-15 (IL-15).

139 locomotor activity through the secretion of interleukin-15 (IL-15).

140 pleted blood lymphocytes and increased serum interleukin-15 (IL-15).

141 ing IFN-gamma, and was mimicked by exogenous interleukin-15 (IL-15).

142 wth factor-B (TGF-B) receptor II and a human interleukin-15 (IL-15)/IL-15 receptor a complex.

143 (T(RM)) transcriptional signature driven by interleukin-15 (IL-15)/IL-21 signaling.

144 a revealed that cytokine support by systemic interleukin-15 (IL-15; N-803) resulted in reduced clinic

145 etreatment of NK cells with a combination of Interleukins-15 (IL-15) and IL-18 prior to cryopreservat

146 s NKTs co-expressing a GD2-specific CAR with interleukin 15 (IL15) (GD2-CAR.15) in 12 children with n

147 Here, we describe a human interleukin 15 (IL15) and human signal regulatory protei

148 18; P < or = .0125), including 5 SNPs in the interleukin 15 (IL15) gene.

149 The common gamma (gammac)-chain cytokine interleukin 15 (IL15) is a multifunctional immune-modula

150 NSG mice that constitutively expresses human Interleukin 15 (IL15), NSG-Tg(Hu-IL15).

151 actors (EGFs) and innate immunity mediators [interleukin 15 (IL15)].

152 The basal expression of interleukin-15 (Il15) in the gingiva and the basal expre

153 Interleukin-15 (IL15) induces proliferation of diverse i

154 Interleukin-15 (IL15) is a cytokine produced by normal b

155 pecific chimeric antigen receptor (CAR) with interleukin-15 in children with relapsed or resistant ne

156 the release of interleukin-2, IFN-gamma, and interleukin-15 in co-culture supernatants.

157 arly devoid of several lineages dependent on interleukin 15, including memory CD8(+) T cells and matu

158 cytokines interleukin-2, interleukin-7, and interleukin-15 increased the antiviral efficacy of CD127

159 cytokines interleukin-7, interleukin-12, and interleukin-15 indicate that these strategies may be use

160 interleukin-4, interleukin-6, interleukin-9, interleukin-15, interferon-gamma, granulocyte-macrophage

161 to be of benefit in animal models, including interleukin-15, interleukin-17, and interleukin-18, and

162 leukin-8, interleukin-10, interleukin-12p70, interleukin-15, interleukin-17A, inducible protein-10, m

163 ffinity, non-cleavable CD16 Fc receptor; and interleukin-15-interleukin-15 receptor fusion.

164 FVIII protein expression is preserved by interleukin-15/interleukin-15 receptor blockade, which s

165 Interleukin 15 is essential for the development and diff

166 Interleukin-15 is a pleiotropic cytokine that is critica

167 nzyme B gene expression by interleukin-2 and interleukin-15 is inhibited by SET knockdown.

168 d cervical mucosal gene expression and lower interleukin 15 levels in women with S. haematobium infec

169 In a subset of 71 participants, interleukin-15 levels (median fluorescent intensity) wer

170 iggered by proinflammatory cytokines such as interleukin-15, macrophage inflammatory protein 1 (MIP-1

171 Co-expression of membrane-bound interleukin 15 (mbIL15) on the T cells enhanced intratum

172 Instead, engineering TIL with membrane-bound interleukin-15 (mbIL15) has the potential to promote TIL

173 a tumor vasculature-targeted CAR and murine interleukin-15 (mIL-15), conferring enhanced effector fu

174 In the resistant mice, interleukin-15 mRNA in the gingiva and Selp mRNA in the

175 igned mimetic of cytokines interleukin-2 and interleukin-15-Neoleukin-2/15 (Neo-2/15)-both for trans-

176 Inhibition of interleukin-15 or of p38 MAP kinase controlled such acti

177 genic situation, and show that inhibition of interleukin-15 or p38 MAP kinase might have the potentia

178 Different combinations of interleukin-15 or signal transduction inhibitors were ad

179 gher levels of interleukin 10 (p = .031) and interleukin 15 (p = .021) than controls before cytomegal

180 Interleukin 15 plays a key role in activation of leukemi

181 after HSCT and favored by the high levels of interleukin-15 present in patients' sera, immature NK ce

182 ed tumour necrosis factor, interleukin-6 and interleukin-15 production and downstream activation of n

183 SCA CAR NK cells also expressing soluble (s) interleukin 15 (PSCA CAR_s15 NK cells) were evaluated in

184 a cell-intrinsic manner 'downstream' of the interleukin 15 receptor (IL-15R) and through the transcr

185 cytokines and cytokine receptors, including interleukin 15 receptor alpha (IL15Ralpha) and, even mor

186 by NKG2D and DAP10 to those initiated by the interleukin 15 receptor.

187 Interleukin-15 receptor alpha (IL-15R alpha) is a pleiot

188 lls, which resembles the T-cell phenotype of interleukin-15 receptor alpha chain (IL-15Ralpha) and IL

189 on, whereas mutations in the Ly108 receptor, interleukin-15 receptor alpha, or the transcription fact

190 ockade of IFN-gamma, interleukin-2 (IL-2) or interleukin-15 receptor beta (IL-15Rbeta) prevented dise

191 ctly represses Cish, a negative regulator of interleukin-15 receptor resulting in impaired interleuki

192 nterleukin-15 receptor resulting in impaired interleukin-15 receptor signaling.

193 e 3, peptidyl arginine deiminase type-2, and interleukin-15 receptor subunit a.

194 vels of the interleukin-7 receptor-alpha and interleukin-15 receptor-alpha by T cells.

195 d production of cytokines, and dependence on Interleukin-15, resembling NKT and other innate T cell l

196 expression of CD122, the receptor specifying interleukin 15 responsiveness.

197 anti-PD-L1 (Avelumab) and recombinant human interleukin-15 (rhIL-15) in SIV-infected rhesus macaques

198 lumab) in combination with recombinant human interleukin-15 (rhIL-15) synergistically enhanced cytoki

199 iption factors STAT5 and RUNX, which promote interleukin-15 signaling and cytolytic programs, and Ikz

200 We demonstrate that both CAR activation and interleukin-15 signalling rapidly induce CREM upregulati

201 gineering of NK cells to express (1) soluble interleukin-15 (sIL15) for enhancing their survival and

202 in the presence of cytokines (interleukin-7, interleukin-15, stem cell factor, and fms-like tyrosine

203 signaling and impaired responses to TCR and interleukin-15 stimulation.

204 atency persistence and reversal, we used the interleukin-15 superagonist N-803 in conjunction with th

205 roduction, under photothermal control, of an interleukin-15 superagonist or a bispecific T cell engag

206 Interleukin-15/T(IL-15) is a growth factor that utilizes

207 expressed higher levels of HS27, HSP70, and interleukin-15 than controls; their IECs also had ultras

208 reconstituted mice require preactivation by interleukin-15 to reach the functional competence of hum

209 Treatment of human interleukin-15 transgenic NSG mice with one of the scDbs

210 uid from women in this village, the level of interleukin 15 was lower in the S. haematobium-infected

211 Levels of heat shock protein (HSP) and interleukin 15 were measured by immunohistochemistry, an

212 intraepithelial lymphocytes was regulated by interleukin 15, which induced local chromatin modificati

213 he NK-stimulatory molecules 4-1BB ligand and interleukin 15, which yielded a median greater than 1000

214 lpha(+) IELs had increased responsiveness to interleukin-15, which explained a substantial part, but

215 Cultured myoblasts were found to produce interleukin-15, which impacts local T-cell activation an